与 2019 年冠状病毒病（COVID-19）疫苗相关的预防接种不良事件：来自 VigiAccess 的描述性分析。
Adverse events following immunization associated with coronavirus disease 2019 (COVID-19) vaccines: A descriptive analysis from VigiAccess.
机构信息
School of Pharmacy, University of Health and Allied Sciences, Ho, Ghana.
College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
出版信息
Hum Vaccin Immunother. 2022 Nov 30;18(6):2109365. doi: 10.1080/21645515.2022.2109365. Epub 2022 Aug 10.
Abstract
This study assessed adverse events following immunizations (AEFIs) reported on COVID-19 vaccines in VigiAccess and determined the reporting trends across all continents of the world. The study was cross-sectional quantitative in design. VigiAccess was searched on 10 November 10 2021 for reported adverse events following the introduction of COVID-19 vaccines. After entering the search term, "COVID-19 vaccines" in VigiAccess, AEFIs associated with nine approved brands of COVID-19 vaccines had been documented in the database. Data were captured among age groups, sex, and continents of the world and analyzed using Statistical Package for Social Sciences (SPSS) version 25. Overall, 2,457,386 AEFIs had been reported in VigiAccess at the time of the search. No causal associations could be established between the vaccines and the AEFIs. The public accessing VigiAccess data should therefore be made aware of this in order to not falsely attribute AEFIs to COVID-19 vaccines when assessing the database.
摘要
本研究评估了 VigiAccess 中报告的 COVID-19 疫苗接种后不良事件（AEFIs），并确定了全球各大洲的报告趋势。该研究采用横断面定量设计。于 2021 年 11 月 10 日在 VigiAccess 中搜索 COVID-19 疫苗引入后报告的不良事件后，在数据库中记录了与九种批准的 COVID-19 疫苗品牌相关的 AEFIs。在年龄组、性别和世界各大洲之间捕获数据，并使用社会科学统计软件包（SPSS）版本 25 进行分析。总体而言，在搜索时，VigiAccess 中已报告了 2,457,386 例 AEFIs。不能确定疫苗与 AEFIs 之间存在因果关系。因此，公众在访问 VigiAccess 数据时应注意这一点，以免在评估数据库时将 AEFIs 错误归因于 COVID-19 疫苗。
相似文献
1
Adverse events following immunization associated with coronavirus disease 2019 (COVID-19) vaccines: A descriptive analysis from VigiAccess.与 2019 年冠状病毒病（COVID-19）疫苗相关的预防接种不良事件：来自 VigiAccess 的描述性分析。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2109365. doi: 10.1080/21645515.2022.2109365. Epub 2022 Aug 10.
2
Adverse Event Following Immunization (AEFI) in Children: An Analysis of Reporting in VigiAccess.疫苗不良反应（AEFI）在儿童：在 VigiAccess 中的报告分析。
Drug Res (Stuttg). 2022 Oct;72(8):435-440. doi: 10.1055/a-1852-5335. Epub 2022 Jun 20.
3
Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands.描述四种不同 COVID-19 疫苗品牌接种后报告的不良事件频率。
Drug Saf. 2022 Apr;45(4):319-331. doi: 10.1007/s40264-022-01151-w. Epub 2022 Mar 21.
4
[Adverse events following immunization reported with COVID-19 vaccines in Burkina Faso: Analysis of spontaneous reports].[布基纳法索新冠疫苗接种后的不良事件：自发报告分析]
Sante Publique. 2024 Feb 23;35(6):149-159. doi: 10.3917/spub.236.0149.
5
Serious adverse event following immunization and thromboembolic events associated with COVID19 vaccination: An analysis of nationwide causality assessment from India.接种后严重不良事件和与 COVID19 疫苗接种相关的血栓栓塞事件：来自印度全国因果关系评估的分析。
Indian Heart J. 2023 Mar-Apr;75(2):139-144. doi: 10.1016/j.ihj.2023.02.004. Epub 2023 Feb 28.
6
Barriers to COVID-19 vaccine surveillance: the issue of under-reporting adverse events.新冠疫苗监测的障碍：不良事件漏报问题。
Epidemiol Health. 2023;45:e2023054. doi: 10.4178/epih.e2023054. Epub 2023 Jun 7.
7
Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands.荷兰 COVID-19 基础免疫和加强免疫后自发报告的不良事件。
Vaccine. 2023 Jun 29;41(29):4319-4326. doi: 10.1016/j.vaccine.2023.05.053. Epub 2023 May 24.
8
Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System.疫苗不良事件自动报告系统中报告的与 2019 年冠状病毒病疫苗接种相关的不良事件。
J Korean Med Sci. 2021 May 3;36(17):e114. doi: 10.3346/jkms.2021.36.e114.
9
COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study.COVID-19 mRNA 疫苗：一项回顾性观察性药物警戒研究。
Clin Drug Investig. 2022 Dec;42(12):1065-1074. doi: 10.1007/s40261-022-01216-9. Epub 2022 Oct 23.
10
Willingness to receive a vaccine is influenced by adverse events following immunisation experienced by others.人们对接种疫苗的意愿受到他人接种后不良反应的影响。
Vaccine. 2023 Jan 4;41(1):246-250. doi: 10.1016/j.vaccine.2022.11.034. Epub 2022 Nov 26.
引用本文的文献
1
Adverse reactions of four multi-targeted tyrosine kinase inhibitors: a descriptive analysis of the WHO-VigiAccess database.四种多靶点酪氨酸激酶抑制剂的不良反应：世界卫生组织药物不良反应数据库的描述性分析
Front Pharmacol. 2025 Apr 22;16:1585862. doi: 10.3389/fphar.2025.1585862. eCollection 2025.
2
Adverse event profile of lomustine and temozolomide: a descriptive analysis from WHO-VigiAccess.洛莫司汀和替莫唑胺的不良事件概况：来自世界卫生组织药物警戒数据库VigiAccess的描述性分析
Front Pharmacol. 2025 Mar 6;16:1534802. doi: 10.3389/fphar.2025.1534802. eCollection 2025.
3
DNA methylation inhibitors adverse reaction characteristic analysis: a descriptive analysis from WHO-VigiAccess.DNA甲基化抑制剂不良反应特征分析：来自世界卫生组织药物警戒数据库VigiAccess的描述性分析
Front Pharmacol. 2024 Oct 2;15:1470148. doi: 10.3389/fphar.2024.1470148. eCollection 2024.
4
A real-world data analysis of ocular adverse events linked to anti-VEGF drugs: a WHO-VigiAccess study.一项关于抗VEGF药物相关眼部不良事件的真实世界数据分析：世界卫生组织药物警戒数据库研究
Front Pharmacol. 2024 Jul 30;15:1398783. doi: 10.3389/fphar.2024.1398783. eCollection 2024.
5
Characteristic analysis of adverse reactions of five anti-TNFɑ agents: a descriptive analysis from WHO-VigiAccess.五种抗TNFɑ药物不良反应的特征分析：来自世界卫生组织药物不良反应数据库（WHO-VigiAccess）的描述性分析
Front Pharmacol. 2023 Jul 24;14:1169327. doi: 10.3389/fphar.2023.1169327. eCollection 2023.
6
Three Doses of COVID-19 Vaccines: A Retrospective Study Evaluating the Safety and the Immune Response in Patients with Multiple Sclerosis.三剂新冠疫苗：一项评估多发性硬化症患者安全性和免疫反应的回顾性研究
J Clin Med. 2023 Jun 23;12(13):4236. doi: 10.3390/jcm12134236.
7
COVID-19 Vaccines and Myocarditis: An Overview of Current Evidence.2019冠状病毒病疫苗与心肌炎：当前证据概述
Biomedicines. 2023 May 17;11(5):1469. doi: 10.3390/biomedicines11051469.
8
Safety Monitoring of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years by Using EudraVigilance Pharmacovigilance Database: The CoVaxChild Study.利用欧洲药物警戒数据库对5至11岁儿童的新冠mRNA疫苗进行安全性监测：CoVaxChild研究
Vaccines (Basel). 2023 Feb 9;11(2):401. doi: 10.3390/vaccines11020401.
本文引用的文献
1
Adverse Reactions to Anti-SARS-CoV-2 Vaccine: A Prospective Cohort Study Based on an Active Surveillance System.抗SARS-CoV-2疫苗的不良反应：基于主动监测系统的前瞻性队列研究
Vaccines (Basel). 2022 Feb 23;10(3):345. doi: 10.3390/vaccines10030345.
2
Why many African countries may not achieve the 2022 COVID-19 vaccination coverage target.为何许多非洲国家可能无法实现2022年新冠疫苗接种覆盖率目标。
Trop Med Health. 2022 Feb 15;50(1):15. doi: 10.1186/s41182-022-00407-6.
3
Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) - highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts.新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异毒株奥密克戎（B.1.1.529）的出现——凸显了非洲的研究能力，但也暴露了重大的知识空白、疫苗分配不公、全球新冠疫情应对和防控工作的不足。
Int J Infect Dis. 2022 Jan;114:268-272. doi: 10.1016/j.ijid.2021.11.040. Epub 2021 Dec 1.
4
Attitude towards COVID 19 vaccines and vaccine hesitancy in urban and rural communities in Tamil Nadu, India - a community based survey.印度泰米尔纳德邦城乡社区对 COVID-19 疫苗的态度和疫苗犹豫——一项基于社区的调查。
BMC Health Serv Res. 2021 Sep 21;21(1):994. doi: 10.1186/s12913-021-07037-4.
5
Higher incidence of reported adverse events following immunisation (AEFI) after first dose of COVID-19 vaccine among previously infected health care workers.既往感染过的医护人员在接种第一剂新冠疫苗后报告的免疫后不良事件（AEFI）发生率较高。
Med J Armed Forces India. 2021 Jul;77(Suppl 2):S505-S507. doi: 10.1016/j.mjafi.2021.05.011. Epub 2021 Jul 26.
6
COVID-19 vaccine hesitancy - reasons and solutions to achieve a successful global vaccination campaign to tackle the ongoing pandemic.新冠病毒疫苗犹豫 - 实现成功的全球疫苗接种运动以应对当前大流行的原因和解决方案。
Hum Vaccin Immunother. 2021 Oct 3;17(10):3495-3499. doi: 10.1080/21645515.2021.1926183. Epub 2021 Jun 30.
7
Second wave of COVID-19 in India: Dissection of the causes and lessons learnt.印度第二波新冠疫情：原因剖析与经验教训
Travel Med Infect Dis. 2021 Sep-Oct;43:102126. doi: 10.1016/j.tmaid.2021.102126. Epub 2021 Jun 16.
8
Mutations in SARS-CoV-2; Consequences in structure, function, and pathogenicity of the virus.SARS-CoV-2 突变；对病毒结构、功能和致病性的影响。
Microb Pathog. 2021 May;154:104831. doi: 10.1016/j.micpath.2021.104831. Epub 2021 Mar 13.
9
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine.接种辉瑞-生物科技公司新冠疫苗第一剂后包括过敏反应在内的过敏反应。
JAMA. 2021 Feb 23;325(8):780-781. doi: 10.1001/jama.2021.0600.
10
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.美国 2020 年 12 月 14 日至 23 日：在接种第一剂辉瑞-BioNTech COVID-19 疫苗后出现过敏反应（包括过敏反应）。
MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):46-51. doi: 10.15585/mmwr.mm7002e1.
Zotero 插件